Bloodstream Infection Testing Market - By Product (Instruments, Reagents & Consumables), Sample Type (Whole Blood, Blood Culture), Technology (PCR, Mass Spectroscopy, In Situ Hybridization), End-use (Hospitals) – Global Forecast, 2024 – 2032

Bloodstream Infection Testing Market - By Product (Instruments, Reagents & Consumables), Sample Type (Whole Blood, Blood Culture), Technology (PCR, Mass Spectroscopy, In Situ Hybridization), End-use (Hospitals) – Global Forecast, 2024 – 2032

Bloodstream Infection Testing Market Size

Bloodstream Infection Testing Market size was valued at around USD 875.1 million in 2023 and is estimated to expand at 4.9% CAGR from 2024 to 2032. Bloodstream infections, also known as bacteremia or sepsis, it is diagnostic procedures and laboratory tests that are performed to identify the presence of bacteria or other microorganisms in the bloodstream.
 

The global rise in the prevalence of infectious diseases, coupled with growing awareness and increasing emphasis on infectious disease diagnostics, stands as key factors propelling the market growth. High population density and limited adherence to hygiene practices increases risk of infectious diseases, that significantly impact the human health. According to the data published by National Institutes of Health in 2022, approximately 250,000 bloodstream infections occur annually across the globe. Thus, increasing prevalence of several infectious diseases is anticipated to impel the market progression.
 

Technological advancements in bloodstream infection testing have significantly enhanced the accuracy, speed, and efficiency of diagnostic processes. Further, advances in molecular diagnostic techniques, such as polymerase chain reaction (PCR) technologies and nucleic acid amplification, enable the direct detection of microbial DNA or RNA, allowing for rapid and specific identification of pathogens. Therefore, technological advancements in bloodstream infection testing are projected to accelerate the market expansion.

Bloodstream Infection Testing Market Trends

The notable increase in healthcare-associated bloodstream infections (HA-BSI) in recent years serves as a driving factor for the market. The surge in cases, particularly attributed to the use of intravascular catheters, has raised significant concerns globally.
 

• As per the World Health Organization (WHO), antimicrobial-resistant pathogens causing bloodstream infections has become the second leading cause of global burdens related to antimicrobial resistance (AMR), resulting in a substantial number of fatalities worldwide.
   
• Healthcare-associated bloodstream infections (HA-BSI) rank second in Europe among healthcare-associated Infections (HAIs) in terms of frequency of disability and early mortality. These results underline the critical need for efficient interventions in the healthcare industry and demonstrate the substantial influence of HA-BSIs on patient outcomes.
   

Bloodstream Infection Testing Market Analysis

The market by product is categorized into reagents & consumables, and instruments. The reagents and consumables segment garnered USD 737.1 million revenue in 2023.
 

• This growth is attributed to ongoing advancements in technologies, such as molecular and immunological reagents, multiplex assays for simultaneous pathogen detection, etc. The key developments include the evolution of advanced reagent technologies, particularly in molecular and genetic testing, to enhance diagnostic accuracy.
   
• The demand for consumables related to point-of-care testing is on the rise, and there's a notable integration of artificial intelligence and bioinformatics for enhanced data analysis. Innovations in packaging for stability, a focus on environmentally friendly options, and collaborations for product development underscore the market's adaptability.
   

Based on sample type, the bloodstream infection testing market is segmented into whole blood and blood culture. The blood culture segment accounted for over 72.6% business share in 2023 and is anticipated to witness significant growth.
 

• Blood culture tests are essential for diagnosis of several infections, including fungal, and bacterial, mycobacterial infections. Both automated and manual techniques are used by healthcare professionals to detect these infections.
   
• Further, the efficiency and speed of obtaining results in the blood culture segment have been significantly boosted by the introduction of automated blood culture systems, enhanced bottle designs, and quicker detection methods. This enhancement has further strengthened the dominance of the blood culture segment.
   

The bloodstream infection testing market by technology is categorized into PCR, mass spectroscopy, in situ hybridization, and other technologies. The PCR segment accounted for around USD 457.1 million revenue size in 2023.
 

• The PCR market is anticipated to develop due to several factors, including the growing frequency of infectious and chronic diseases, the need for more sophisticated bloodstream infection detection techniques, and the expansion of forensic and research laboratories is anticipated to accelerate the segmental growth.
   
• Moreover, the development of technologically advanced PCR tests, increasing prevalence of targeted diseases, government initiatives, and application expansion of existing technologies are projected to drive the segment.
   

Based on end-use, the bloodstream infection testing market is segmented into hospitals & diagnostic centers, academic & research institutes, and other end-users. The hospitals & diagnostic centers segment accounted for over 45.3% business share in 2023 and is anticipated to witness significant growth during the forecast period.
 

• Bloodstream infections are still very difficult to diagnose and treat, but hospitals are at the forefront of this field. Accurate and fast bloodstream infection testing is becoming more and more important in order to guide treatment decisions in light of the growing number of sepsis cases and hospital-acquired infections. This propels the demand for bloodstream infection testing services in hospitals.
   
• To improve and expedite their bloodstream infection testing capabilities, hospitals frequently work with diagnostic labs and testing suppliers. These partnerships combine the knowledge and assets of the two organizations, improving patient care, testing capacity, and diagnostic accuracy. Because of these collaborations, the market is growing and there is a greater demand for blood testing services.
   

North America bloodstream infection testing market accounted for USD 381.6 million revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• The growth is majorly owing to the region's increasing disposable income, favorable reimbursement policies, highly developed health infrastructure, product launches and increasing strategic initiatives by the major companies operating in the market.
   
• Furthermore, rising prevalence of infectious diseases and awareness regarding early disease diagnosis will drive the market trends.
   

Bloodstream Infection Testing Market Share

The bloodstream infection testing industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc, among others have a notable presence in the market.
 

Bloodstream Infection Testing Market Companies

Some of the eminent market participants operating in the bloodstream infection testing industry include

• Abbott Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Bruker Corporation
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Luminex Corporation
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
   

Bloodstream Infection Testing Industry News

• In July 2022, T2 Biosystems, Inc., a prominent firm that specializes in the early detection of sepsis-causing antibiotic resistance genes and microorganisms, has obtained a grant from the U.S. Food and Drug Administration (FDA) for their T2Lyme panel. This panel empowers physicians to ensure prompt administration of suitable therapy to patients, simultaneously averting the adverse effects of treatment and the overuse of antibiotics.
   

Bloodstream infection testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product

• Reagents & consumables
• Instruments

Market, By Sample Type

• Whole blood
• Blood culture

Market, By Technology

• PCR
• Mass spectroscopy
• In situ hybridization
• Other technologies

Market, By End-use

• Hospitals & diagnostic centers
• Academic & research institutes
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa